Neurocrine Biosciences Presents New INGREZZA® (valbenazine) Capsules Data Demonstrating Early and Sustained Improvements in Chorea Associated With Huntington’s Disease
![img: Featured](/wp-content/themes/neurocrine/assets/img/feature-5.jpg)
Data Presented at the 2023 MDS International Congress of Parkinson’s Disease and Movement Disorders ® SAN DIEGO , Aug. 28, 2023 /PRNewswire/ — Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced new data on now FDA-approved INGREZZA ® (valbenazine) capsules for the treatment of adults with